Ireland regulator reports manufacturing deficiency at Biocon's Bengaluru plant
- Country:
- India
Biotechnology major Biocon Biologics on Tuesday said Ireland's health regulator has reported some deficiencies in the manufacturing process at the company's plant in Bengaluru.
The Health Products Regulatory Authority (HPRA), Ireland, conducted a GMP (Good Manufacturing Practice) inspection of one of Biocon Biologics' new monoclonal antibody drug substance manufacturing facilities in Biocon Park, Bengaluru, between March 28 and April 1, 2022, a Biocon Biologics spokesperson said in a regulatory filing.
''The inspection report contains no 'critical' observations and only one of the deficiencies is categorised as 'major' which is being addressed expeditiously in consultation with the regulatory agency,'' the spokesperson added.
The facility will help the company address the additional requirements of products in the European Union market, the spokesperson noted.
Biocon Biologics is a subsidiary of Biocon Ltd.
ALSO READ
-
ILO Türkiye Workshop Spotlights Civil Society’s Role in Defending Workers’ Rights
-
€40m Boost Opens New Doors for Cultural and Creative Businesses in Belgium
-
Belize Communities Take the Lead in New Push for Jobs, Skills and Stronger Futures
-
Hotter Years, More Cavities? Understanding Link Between Climate and Dental Health
-
Europe’s Rare Earth Wake-Up Call: Turning Years of Research Into Factories That Last
Google News